Literature DB >> 19364874

Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits.

Rabih O Darouiche1, Mohammad D Mansouri, Marlowe J Schneidkraut.   

Abstract

Telavancin is an investigational lipoglycopeptide antibiotic that is active against gram-positive pathogens. In an in vivo rabbit model, subtherapeutic (15-mg/kg) and therapeutic (30- or 45-mg/kg) doses of telavancin were demonstrated to be noninferior and superior to vancomycin (20 mg/kg), respectively, for preventing subcutaneous implant colonization and infection by Staphylococcus aureus.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19364874      PMCID： PMC2687217          DOI： 10.1128/AAC.01101-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Device-associated infections: a macroproblem that starts with microadherence.

Authors:  R O Darouiche
Journal:  Clin Infect Dis       Date:  2001-09-26       Impact factor: 9.079

2.  In vitro activity and in vivo efficacy of antimicrobial-coated vascular grafts.

Authors:  Rabih O Darouiche; Mohammad D Mansouri
Journal:  Ann Vasc Surg       Date:  2004-07       Impact factor: 1.466

3.  Three-year experience with sonicated vascular catheter cultures in a clinical microbiology laboratory.

Authors:  R J Sherertz; I I Raad; A Belani; L C Koo; K H Rand; D L Pickett; S A Straub; L L Fauerbach
Journal:  J Clin Microbiol       Date:  1990-01       Impact factor: 5.948

4.  Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.

Authors:  Martin E Stryjewski; William D O'Riordan; William K Lau; Francis D Pien; Lala M Dunbar; Marc Vallee; Vance G Fowler; Vivian H Chu; Elizabeth Spencer; Steven L Barriere; Michael M Kitt; Christopher H Cabell; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2005-04-28       Impact factor: 9.079

5.  Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo.

Authors:  R O Darouiche; M D Mansouri
Journal:  J Infect       Date:  2005-04       Impact factor: 6.072

6.  Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.

Authors:  Sharath S Hegde; Noe Reyes; Tania Wiens; Nicole Vanasse; Robert Skinner; Julia McCullough; Koné Kaniga; John Pace; Roger Thomas; Jeng-Pyng Shaw; Glen Obedencio; J Kevin Judice
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

7.  In vivo efficacy of antimicrobial-coated fabric from prosthetic heart valve sewing rings.

Authors:  R O Darouiche; R Meade; M Mansouri; I I Raad
Journal:  J Heart Valve Dis       Date:  1998-11

8.  Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.

Authors:  Martin E Stryjewski; Donald R Graham; Samuel E Wilson; William O'Riordan; David Young; Arnold Lentnek; Douglas P Ross; Vance G Fowler; Alan Hopkins; H David Friedland; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

9.  Comparative study of cefazolin, cefamandole, and vancomycin for surgical prophylaxis in cardiac and vascular operations. A double-blind randomized trial.

Authors:  D G Maki; M J Bohn; S M Stolz; G M Kroncke; C W Acher; P D Myerowitz
Journal:  J Thorac Cardiovasc Surg       Date:  1992-11       Impact factor: 5.209

10.  Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.

Authors:  Anna King; Ian Phillips; Koné Kaniga
Journal:  J Antimicrob Chemother       Date:  2004-03-17       Impact factor: 5.790
View more
  3 in total

1.  Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.

Authors:  Yan Q Xiong; Wessam Abdel Hady; Arnold S Bayer; Liang Chen; Barry N Kreiswirth; Soo-Jin Yang
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

2.  Suitability of Biomorphic Silicon Carbide Ceramics as Drug Delivery Systems against Bacterial Biofilms.

Authors:  P Díaz-Rodríguez; A Pérez-Estévez; R Seoane; P González; J Serra; M Landin
Journal:  ISRN Pharm       Date:  2013-07-07

3.  A rabbit osteomyelitis model for the longitudinal assessment of early post-operative implant infections.

Authors:  Jim C E Odekerken; Jacobus J C Arts; Don A M Surtel; Geert H I M Walenkamp; Tim J M Welting
Journal:  J Orthop Surg Res       Date:  2013-11-04       Impact factor: 2.359
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.